Four drugs used to treat Alzheimer’s have short-term benefits that are lost after a year and a half of treatment. UTMB’s David Niesel and Norbert Herzog look at a new drug called aducanumab that sharply reduced cognitive decline in patients with early symptoms of dementia in a small clinical trial. This news also reported in The Abilene Reporter-News.